Biochemical Target and Mechanism of Action
The site of action for indirect anticoagulants is the liver. Normally, the active form of vitamin K (hydroquinone) acts as a coenzyme in the $\gamma$-carboxylation of glutamic acid residues (converting them into gamma-carboxyglutamic acid). This process is critical for producing functionally competent clotting factors (II, VII, IX, and X) capable of binding calcium.
During carboxylation, hydroquinone is oxidized into inactive epoxide. For reuse, it must be reduced back by the enzymes vitamin K reductase, epoxide reductase, and DT-diaphorase.
These drugs block these reductase enzymes. As a result, active vitamin K stores are depleted, and the maturation of clotting factors (particularly prothrombin) is halted.
Time Characteristics and Cumulation
A pharmacodynamic feature of this group is a pronounced latent period. The action develops slowly, with maximum effect (e.g., for acenocoumarol) achieved after 48 hours or more.
This delay occurs because the drugs do not affect already circulating proteins. The anticoagulant effect manifests only as existing prothrombin complex factors undergo natural degradation (breakdown).
After drug discontinuation, the effect persists for a prolonged period—about 2–5 days. Additionally, these medications exhibit material cumulation (accumulation of the substance itself in the body).
Pharmacokinetics and Metabolism of Warfarin
These drugs are administered orally (per os), have high bioavailability (about 90%), and a very high plasma protein binding rate (90–95%). Metabolism occurs in the liver via the cytochrome P-450 system. The half-life ranges from 30 to 60 hours.
Warfarin is a racemic mixture:
- S-isomer is 4–5 times more active than the R-isomer and is oxidized exclusively by the CYP 2C9 isoenzyme.
- R-isomer is metabolized by other isoenzymes (CYP 2C19, 3A4).
Genetic polymorphism of the CYP 2C9 isoenzyme is the primary reason for interindividual differences in sensitivity to warfarin and the magnitude of the anticoagulant effect among patients.
Clinical Application and Safety
Indications: Long-term prevention and treatment of deep vein thrombosis, pulmonary embolism, and myocardial infarction. They are also used to prevent thrombosis in the postoperative period, in atrial fibrillation, and after heart valve replacement.
Side Effects: The most frequent complication is bleeding. The risk increases significantly with concurrent antiplatelet therapy (e.g., aspirin). Allergic reactions, diarrhea, impaired liver function, and specific skin necrosis are possible. Phenindione additionally carries a risk of bone marrow suppression.
Interactions: Due to high protein binding, anticoagulants can be displaced by other drugs (e.g., sulfonamides). This leads to an increased free fraction of the anticoagulant and a sharp risk of bleeding.
Pregnancy: Strictly contraindicated. They easily cross the placental barrier and exert a teratogenic effect (inhibiting the formation of the vitamin-K-dependent bone matrix protein osteocalcin, disrupting skeletal development). However, warfarin poorly penetrates breast milk and is permissible during lactation.
Emergency Management of Bleeding
To stop bleeding caused by an overdose of indirect anticoagulants, the following are used:
- Vitamin $K_1$ preparations — act as a pathogenetic antidote.
- Prothrombin complex concentrate — provides rapid replenishment of clotting factor deficiencies (contains vitamin-K-dependent factors II, VII, IX, and X).